Life's essential 8 and mortality in US adults with metabolic dysfunction-associated steatotic liver disease

被引:0
|
作者
Zhang, Yingying [1 ]
Wang, Pingping [2 ]
Tu, Fan [1 ]
Kang, Hao [3 ]
Fu, Chengfeng [4 ]
机构
[1] Jiangnan Univ, Affiliated Wuxi Hosp 5, Med Lab Ctr, 1215 Guangrui Rd, Wuxi 214005, Jiangsu, Peoples R China
[2] Yangzhou Univ, Taizhou Peoples Hosp 2, Dept Clin Lab, Taizhou, Jiangsu, Peoples R China
[3] Jiangnan Univ, Affiliated Wuxi Hosp 5, Res Ctr Clin Med Sci, Wuxi, Jiangsu, Peoples R China
[4] Second Peoples Hosp Banan Dist, Resp & Crit Care Med, 18 Huaxi New Village,Huaxi St, Chongqing 400054, Peoples R China
关键词
MASLD; Life's essential 8; All-cause mortality; CVD mortality; National health and nutrition examination survey; AMERICAN HEART ASSOCIATIONS; CARDIOVASCULAR HEALTH; METAANALYSIS; OUTCOMES; METRICS; NHANES; RISK;
D O I
10.1186/s12889-024-20919-6
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Background Metabolic dysfunction-associated steatotic liver disease (MASLD) is linked to increased all-cause mortality due to metabolic dysfunctions like obesity, diabetes, and cardiovascular diseases. This study examines the association between Life's Essential 8 (LE8) scores and both all-cause and cardiovascular disease (CVD) mortality in MASLD participants. Methods Data from 5,916 MASLD participants in the NHANES (2005-2018) were analyzed. Associations between LE8 scores and all-cause and CVD mortality were assessed using Cox proportional hazards models, with follow-up until December 31, 2019. Dose-response relationships and survival differences were evaluated using Kaplan-Meier survival curves and Restricted Cubic Spline models. Results Over a median follow-up of 7.6 years, moderate and high LE8 scores were associated with 33% (HR: 0.67; 95% CI: 0.56-0.79) and 47% (HR: 0.53; 95% CI: 0.33-0.84) lower risk of all-cause mortality, respectively, compared to low scores. For CVD mortality, the adjusted HRs were 0.56 (95% CI: 0.41-0.78) and 0.35 (95% CI: 0.12-1.0). Higher LE8 scores were significantly associated with reduced cumulative incidence of all-cause and CVD mortality (log-rank P < 0.001). A 10-point increase in health behavior scores, particularly in diet, physical activity, and nicotine exposure, was linked to an 11% reduction in all-cause mortality risk and an 11% reduction in CVD mortality risk. Among health factors, only blood glucose showed a significant association with CVD mortality. Conclusion Higher LE8 scores in MASLD patients are associated with lower mortality risk, suggesting the potential value of promoting cardiovascular health in this population. Further research is needed to confirm these associations.
引用
收藏
页数:12
相关论文
共 50 条
  • [41] Metabolic dysfunction-associated steatotic liver disease in older adults is associated with frailty and social disadvantage
    Clayton-Chubb, Daniel
    Kemp, William W.
    Majeed, Ammar
    Lubel, John S.
    Woods, Robyn L.
    Tran, Cammie
    Ryan, Joanne
    Hodge, Alexander
    Schneider, Hans G.
    Mcneil, John J.
    Roberts, Stuart K.
    LIVER INTERNATIONAL, 2024, 44 (01) : 39 - 51
  • [42] Metabolic dysfunction-associated steatotic liver disease increases cardiovascular disease risk in young adults
    Chung, Goh Eun
    Yu, Su Jong
    Yoo, Jeong-Ju
    Cho, Yuri
    Lee, Kyu-na
    Shin, Dong Wook
    Kim, Yoon Jun
    Yoon, Jung-Hwan
    Han, Kyungdo
    Cho, Eun Ju
    SCIENTIFIC REPORTS, 2025, 15 (01):
  • [43] Metabolic dysfunction-associated steatotic liver disease and risk of cardiovascular disease
    Lee, Hyeok-Hee
    Lee, Han Ah
    Kim, Eun-Jin
    Kim, Hwi Young
    Kim, Hyeon Chang
    Ahn, Sang Hoon
    Lee, Hokyou
    Kim, Seung Up
    GUT, 2024, 73 (03) : 533 - 540
  • [44] Monitoring disease progression in metabolic dysfunction-associated steatotic liver disease
    Noureddin, Nabil
    Copur-Dahi, Nedret
    Loomba, Rohit
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2024, 59 : S41 - S51
  • [45] The association between estimated glucose disposal rate and metabolic dysfunction-associated steatotic liver disease and liver fibrosis in US adults
    Liu, Wanqian
    Li, Xiaozhong
    Chen, Ling
    Luo, Xiao
    BMC ENDOCRINE DISORDERS, 2025, 25 (01)
  • [46] Implications of the new nomenclature of steatotic liver disease and definition of metabolic dysfunction-associated steatotic liver disease
    Loomba, Rohit
    Wong, Vincent Wai-Sun
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2024, 59 (02) : 150 - 156
  • [47] Current Burden of Lean Metabolic Dysfunction-Associated Steatotic Liver Disease Among US Adults, 2017-2023
    Kim, Donghee
    Danpanichkul, Pojsakorn
    Wijarnpreecha, Karn
    Cholankeril, George
    Loomba, Rohit
    Ahmed, Aijaz
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2025, 61 (05) : 891 - 894
  • [48] Quality of Life in Adults with Metabolic Dysfunction-Associated Fatty Liver Disease
    Hwang, Tae-In
    Han, A-Lum
    INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH, 2021, 18 (24)
  • [49] ASSOCIATION BETWEEN METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE AND MORTALITY: A NATIONWIDE COHORT STUDY
    Kim, Gi-Ae
    Park, Yewan
    Jung, Jooyi
    HEPATOLOGY, 2024, 80 : S880 - S880
  • [50] Prevalence of Metabolic Dysfunction-associated Steatotic Liver Disease and Cardiometabolic Risk Factor in US Adolescents
    Zheng, Xiaoyan
    Zhao, Dongying
    Wang, Liwei
    Wang, Yiwen
    Chen, Yan
    Zhang, Yongjun
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2024,